Skye Bioscience, Inc.
SKYEAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Oct 6, 2025 | Craig-Hallum | $2.00(+6%) | $1.88 | TheFly | |
| Oct 6, 2025 | Cantor Fitzgerald | $2.00(-5%) | $2.12 | TheFly | |
| Sep 10, 2024 | JMP Securities | Jonathan Wolleben | $15.00(+136%) | $6.35 | TheFly |
| Aug 26, 2024 | Craig-Hallum | Albert Lowe | $18.00(+202%) | $5.97 | StreetInsider |
| Jun 10, 2024 | Oppenheimer | Jay Olson | $21.00(+110%) | $9.98 | StreetInsider |
| May 23, 2024 | Cantor Fitzgerald | Kristen Kluska | $21.00(+75%) | $11.98 | TheFly |
| Apr 11, 2024 | Oppenheimer | Jay Olson | $25.00(+97%) | $12.69 | StreetInsider |
| Mar 14, 2024 | Piper Sandler | Edward Tenthoff | $20.00(+55%) | $12.90 | StreetInsider |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| JMP Securities | maintain | Market Outperform | Jun 24, 2025 |
| Craig-Hallum | maintain | Buy | Mar 21, 2025 |
| Citizens Capital Markets | maintain | Market Outperform | Mar 21, 2025 |
| Piper Sandler | maintain | Overweight | Sep 20, 2024 |
| Cantor Fitzgerald | maintain | Overweight | Sep 20, 2024 |
| Cantor Fitzgerald | maintain | Overweight | Sep 9, 2024 |
| Cantor Fitzgerald | maintain | Overweight | Sep 6, 2024 |
| Cantor Fitzgerald | maintain | Overweight | Aug 27, 2024 |
| Cantor Fitzgerald | maintain | Overweight | Jul 1, 2024 |
| Cantor Fitzgerald | maintain | Overweight | Jun 18, 2024 |
| Cantor Fitzgerald | maintain | Overweight | Jun 17, 2024 |
| Piper Sandler | maintain | Overweight | Mar 14, 2024 |
Earnings History
Next report: Mar 25, 2027 · EPS est. $-1.06| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 14, 2026 | $-2.16 | $-2.04 | — | — |
| May 11, 2026 | $-0.32 | $-0.29 | — | — |
| Mar 19, 2026 | $-2.88 | $-2.32 | — | — |
| Nov 10, 2025 | $-2.56 | $-2.64 | — | — |
| Aug 8, 2025 | $-0.44 | $-2.72 | — | — |
| May 8, 2025 | $-0.28 | $-2.48 | — | — |
| Mar 20, 2025 | $-0.24 | $-2.24 | — | — |
| Nov 7, 2024 | $-0.10 | $-2.00 | — | — |
News
Skye Bioscience, Inc. (NASDAQ: SKYE - Get Free Report) major shareholder 5Am Partners Vii, Llc sold 33,892 shares of Skye Bioscience stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $1.91, for a total transaction of $64,733.72. Following the completion of the sale, the insider directly owned 5,616
Skye Bioscience, Inc. (NASDAQ: SKYE - Get Free Report) Director Andrew Schwab sold 33,892 shares of Skye Bioscience stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $1.91, for a total transaction of $64,733.72. Following the completion of the transaction, the director directly owned 5,616 shares in the
Skye Bioscience (NASDAQ: SKYE) and privately held Redx announced a definitive transaction agreement that would combine the companies into a Nasdaq-listed fibrosis-focused biotechnology company named Fibrx Therapeutics. The transaction, unanimously approved by both companies' boards, is expected to close in the fourth quarter of 2026, subject to shareholder approvals, customary closing conditions, approval of the Redx
Skye Bioscience, Inc. (SKYE) M&A Call Prepared Remarks Transcript
Combined company to trade on Nasdaq and operate as Fibrx Therapeutics, a fibrosis-focused company led by the Redx management team and board Company's lead program will be RXC008, Redx's GI-restricted pan-ROCK inhibitor for the treatment of fibrostenotic Crohn's disease, with an open U.S. IND, FDA Fast Track designation, and a planned Phase 2 clinical study Concurrent aggregate financings of approximately $125 million committed by a syndicate of new and existing leading healthcare institutional i…